PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA भारत सरकार

Hindu, Delhi Tuesday 3rd February 2015, Page: 14 Width: 7.99 cms, Height: 4.56 cms, a4, Ref: pmin.2015-02-03.38.99

Lupin gests USFDA nod for diarrhoea drug

MUMBAI: Lupin, on Monday, said it had received the final approval from the United States Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals' Vancocin capsules of 125 mg and 250 mg strengths. The product is used to treat C.difficileassociated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Vancocin capsules had annual U.S. sales of \$164.2 million (IMS September, 2014). Lupin's U.S. subsidiary Lupin Pharmaceuticals Inc. will commence marketing the product shortly. - Special Correspondent

Company